Developer docs
API playgroundTry for free, no card

Search company profiles

Avvio Medical

Full company profile

uuid003krt3

Namestring
Avvio Medical
Legal namestring
Avvio Medical, Inc.
Websiteurl
avviomed.com
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
kidney stone treatment, microbubble sonolithotripsy, ultrasound lithotripsy devices, minimally invasive urology, outpatient stone management
Industry1 code
1Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
CodeHLAHADANPrimaryYes
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Urology Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Avvio Enhanced Lithotripsy System (ELS)
Description

Utilizes microbubble enhanced acoustic cavitation to treat kidney stones outside traditional hospital settings.

mpo-mag.com
+1 more record
Core offering1 text field

Avvio Medical is a clinical-stage medical device company developing the Avvio Enhanced Lithotripsy System (ELS), which uses patented microbubbles actuated by low-intensity ultrasound to break ureteral and kidney stones into smaller passable particles. The technology enables an outpatient procedure that eliminates the need for routine general anesthesia and ureteral stents, allowing treatment in clinics and rural settings rather than only in specialized hospital facilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Accelerates stone care from weeks to days
+3 more records
Product overview1 text field

Avvio Medical offers a single unified product: the Avvio Enhanced Lithotripsy System (ELS), which implements Microbubble SonoLithotripsy technology. This is a medical device system that uses low-intensity ultrasound to actuate patented microbubbles, which accumulate near kidney stones and cavitate to break them into passable fragments. The technology is designed as a minimally invasive outpatient procedure that eliminates the need for routine general anesthesia or ureteral stents, potentially enabling treatment in outpatient clinics or rural settings. The company is in clinical stage with pivotal ELS study actively enrolling and FDA market clearance anticipated in 2026.

Product and service1 record
1Avvio Enhanced Lithotripsy System (ELS)
CategoryLithotripsy / Urology Medical Devices
Description

Medical device system implementing Microbubble SonoLithotripsy, in which low-intensity ultrasound actuates patented microbubbles that accumulate near kidney or ureteral stones and cavitate to fragment them into passable particles. Designed for outpatient use by urologists, without routine general anesthesia or ureteral stents, enabling treatment in clinics or rural settings.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1EDAP TMS
TypeDirect peer
Description

EDAP TMS is a direct lithotripsy competitor with established extracorporeal shockwave and HIFU systems for urology and oncology. Both companies target kidney stone treatment with energy-based modalities, making them the closest head-to-head peer for Avvio's ultrasound-based ELS.

2Lumenis (Boston Scientific)
TypeDirect peer
Description

Lumenis is a leading manufacturer of holmium and thulium laser systems used in ureteroscopy and laser lithotripsy for stone treatment. Directly comparable as a modality competitor (laser lithotripsy vs. microbubble ultrasound) for ureteral stones.

3Richard Wolf
TypeBroad incumbent
Description

Richard Wolf is a specialist in endoscopic urology equipment including ureteroscopy systems and stone disintegration devices. Comparable as a focused incumbent in the urology procedure space.

4Applaud Medical
TypeEmerging player
Description

Applaud Medical is developing microbubble-enhanced ultrasound-based stone fragmentation technologies, mirroring Avvio's mechanism. Highly relevant emerging peer pursuing the same novel cavitation approach to lithotripsy.

5Cook Medical
TypeBroad incumbent
Description

Cook Medical has a broad urology portfolio including ureteral stents, stone extraction devices, and ureteroscopy accessories — directly relevant as an incumbent supplier of consumables used in current standard-of-care stone treatment.

6Olympus Corporation
TypeBroad incumbent
Description

Olympus is a dominant player in urology endoscopy and flexible ureteroscopy systems used for ureteral stone treatment. Comparable as an entrenched broad incumbent in the urological device space where Avvio will compete.

7Boston Scientific
TypeBroad incumbent
Description

Boston Scientific has a large urology and pelvic health portfolio including stone management devices, holmium laser systems, and ureteroscopes. Comparable as a broad incumbent whose stone management franchise could be a competitor or strategic acquirer of Avvio.

8SonoMotion
TypeEmerging player
Description

SonoMotion is developing ultrasound-based stone repositioning and comminution technologies (e.g., Propulse, Burst Wave Lithotripsy). Directly comparable as another ultrasound-based emerging approach to non-invasive kidney stone treatment.

9Karl Storz
TypeBroad incumbent
Description

Karl Storz is a leading manufacturer of rigid and flexible endoscopes, ureteroscopes, and visualization systems used in ureteroscopy for stone management. Comparable as a broad incumbent in the urology endoscopy space where Avvio's ELS would be an alternative.

10Dornier MedTech
TypeDirect peer
Description

Dornier is a pioneer and established player in ESWL (extracorporeal shockwave lithotripsy) systems used worldwide for kidney stone treatment. Comparable as a focused lithotripsy competitor with installed hospital base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avvio Medical

Urology Medical Devicesavviomed.com

Avvio Medical firmographics

Firmographics
Name
Avvio Medical
Legal name
Avvio Medical, Inc.
Website
https://avviomed.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Avvio Medical industry classification

Industry
Product category
Urology Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro primary industry
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

Keywords

  • Kidney stone treatment
  • Microbubble sonolithotripsy
  • Ultrasound lithotripsy devices
  • Minimally invasive urology
  • Outpatient stone management

Where Avvio Medical is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Avvio Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Avvio Medical product offering

Product offering

Core offering

Avvio Medical is a clinical-stage medical device company developing the Avvio Enhanced Lithotripsy System (ELS), which uses patented microbubbles actuated by low-intensity ultrasound to break ureteral and kidney stones into smaller passable particles. The technology enables an outpatient procedure that eliminates the need for routine general anesthesia and ureteral stents, allowing treatment in clinics and rural settings rather than only in specialized hospital facilities.

Product overview

Avvio Medical offers a single unified product: the Avvio Enhanced Lithotripsy System (ELS), which implements Microbubble SonoLithotripsy technology. This is a medical device system that uses low-intensity ultrasound to actuate patented microbubbles, which accumulate near kidney stones and cavitate to break them into passable fragments. The technology is designed as a minimally invasive outpatient procedure that eliminates the need for routine general anesthesia or ureteral stents, potentially enabling treatment in outpatient clinics or rural settings. The company is in clinical stage with pivotal ELS study actively enrolling and FDA market clearance anticipated in 2026.

Differentiator

Problem solved

Functional benefit

Brands

  • Avvio Enhanced Lithotripsy System (ELS): Utilizes microbubble enhanced acoustic cavitation to treat kidney stones outside traditional hospital settings.
  • Microbubble SonoLithotripsy

Products and services

  • Avvio Enhanced Lithotripsy System (ELS) Medical device system implementing Microbubble SonoLithotripsy, in which low-intensity ultrasound actuates patented microbubbles that accumulate near kidney or ureteral stones and cavitate to fragment them into passable particles. Designed for outpatient use by urologists, without routine general anesthesia or ureteral stents, enabling treatment in clinics or rural settings.

Quantifiable outcome

  • Accelerates stone care from weeks to days
  • +3 more outcomes

Companies that use Avvio Medical

Customer profile

Segments2 records

Ideal customer profiles2 records

Avvio Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Avvio Medical partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Avvio Medical competitors and assessment

Company assessment

Direct peers

  • EDAP TMS: EDAP TMS is a direct lithotripsy competitor with established extracorporeal shockwave and HIFU systems for urology and oncology. Both companies target kidney stone treatment with energy-based modalities, making them the closest head-to-head peer for Avvio's ultrasound-based ELS.
  • Lumenis (Boston Scientific): Lumenis is a leading manufacturer of holmium and thulium laser systems used in ureteroscopy and laser lithotripsy for stone treatment. Directly comparable as a modality competitor (laser lithotripsy vs. microbubble ultrasound) for ureteral stones.
  • Dornier MedTech: Dornier is a pioneer and established player in ESWL (extracorporeal shockwave lithotripsy) systems used worldwide for kidney stone treatment. Comparable as a focused lithotripsy competitor with installed hospital base.

Broad incumbents

  • Richard Wolf: Richard Wolf is a specialist in endoscopic urology equipment including ureteroscopy systems and stone disintegration devices. Comparable as a focused incumbent in the urology procedure space.
  • Cook Medical: Cook Medical has a broad urology portfolio including ureteral stents, stone extraction devices, and ureteroscopy accessories — directly relevant as an incumbent supplier of consumables used in current standard-of-care stone treatment.
  • Olympus Corporation: Olympus is a dominant player in urology endoscopy and flexible ureteroscopy systems used for ureteral stone treatment. Comparable as an entrenched broad incumbent in the urological device space where Avvio will compete.
  • Boston Scientific: Boston Scientific has a large urology and pelvic health portfolio including stone management devices, holmium laser systems, and ureteroscopes. Comparable as a broad incumbent whose stone management franchise could be a competitor or strategic acquirer of Avvio.
  • Karl Storz: Karl Storz is a leading manufacturer of rigid and flexible endoscopes, ureteroscopes, and visualization systems used in ureteroscopy for stone management. Comparable as a broad incumbent in the urology endoscopy space where Avvio's ELS would be an alternative.

Emerging players

  • Applaud Medical: Applaud Medical is developing microbubble-enhanced ultrasound-based stone fragmentation technologies, mirroring Avvio's mechanism. Highly relevant emerging peer pursuing the same novel cavitation approach to lithotripsy.
  • SonoMotion: SonoMotion is developing ultrasound-based stone repositioning and comminution technologies (e.g., Propulse, Burst Wave Lithotripsy). Directly comparable as another ultrasound-based emerging approach to non-invasive kidney stone treatment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Avvio Medical social profiles

Digital presence

Avvio Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avvio Medical leadership team

Management profile

Number of profiles

Avvio Medical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avvio Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avvio Medical

What does Avvio Medical do?

Avvio Medical is a clinical-stage medical device company developing the Avvio Enhanced Lithotripsy System (ELS), which uses patented microbubbles actuated by low-intensity ultrasound to break ureteral and kidney stones into smaller passable particles. The technology enables an outpatient procedure that eliminates the need for routine general anesthesia and ureteral stents, allowing treatment in clinics and rural settings rather than only in specialized hospital facilities.

Is Avvio Medical a public or private company?

Avvio Medical is a private company. It is classified as unknown and is currently operating.

When was Avvio Medical founded?

Avvio Medical was founded in 2014. It employs 11 to 50 people.

Where is Avvio Medical based?

Avvio Medical is headquartered in San Francisco, United States, in the North America region.

Who are Avvio Medical's main competitors?

Direct peers on record are EDAP TMS, Lumenis (Boston Scientific) and Dornier MedTech. Broad incumbents are Richard Wolf, Cook Medical, Olympus Corporation, Boston Scientific and Karl Storz. Emerging players are Applaud Medical and SonoMotion.

Does Avvio Medical have an API?

No public API is recorded for Avvio Medical.

What industry is Avvio Medical in?

Avvio Medical's product category is Urology Medical Devices. Its primary akta.pro industry code is HLAHADAN, Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogAvvio Medical Establishes New Ureteral Stone Treatment Vertical at AUA 2026 Annual MeetingAvvio Medical, a clinical-stage medical device company, participated as a showcase presenter at the 2026 American Urological Association Annual Meeting in Washington, DC, introducing its Microbubble SonoLithotripsy technology for ureteral stone treatment. The company conducted approximately 40 high-value meetings with urologists, investors, and medtech strategics, generating significant interest in what it claims is the first fundamentally new therapeutic approach in this field in over 30 years. Avvio Medical's pivotal ELS study is actively enrolling across U.S. sites and remains on track toward FDA market clearance, with early results described as encouraging.Mpo-magAvvio Gains FDA Breakthrough Status for Enhanced Lithotripsy SystemAvvio Medical received FDA Breakthrough Device designation for its Avvio Enhanced Lithotripsy System (ELS), a kidney stone treatment technology using microbubble-enhanced acoustic cavitation that enables procedures in outpatient settings without general anesthesia. The company is conducting a pivotal trial under an active investigational device exemption and plans a De Novo submission to FDA early next year with a targeted U.S. launch in 2026. The designation validates the technology's clinical evidence and provides a collaborative pathway with FDA reviewers for market clearance.Business Wire BlogAvvio Medical Receives FDA Breakthrough Device Designation for the Avvio Enhanced Lithotripsy System (ELS)The U.S. Food and Drug Administration granted Breakthrough Device Designation to Avvio Medical's Enhanced Lithotripsy System (ELS), a kidney stone treatment technology that enables outpatient procedures without general anesthesia. The designation provides priority FDA engagement and an accelerated review pathway, with the company preparing for a De Novo submission in early 2026 and subsequent U.S. commercial launch. The system aims to expand access to minimally invasive stone treatment for patients affected by ureteral stones, particularly the Medicare-aged population disproportionately represented in stone disease incidence.AInvestAvvio Medical Secures New CPT Code for Breakthrough Kidney Stone Treatment TechnologyAvvio Medical secured a new CPT code (0991T) for its kidney stone treatment technology, effective January 1, 2026. The American Medical Association published the code as part of its Category III CPT Code Early Release. The code reflects progress in bringing the technology to patients and providers.